Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07184632 | A Research Study on How Well Different Doses of the Medicine NNC0662-0419 Help People Living With Overweight or Obesity | PHASE2 | ACTIVE NOT_RECRUITING | 224 | — | — | Oct 1, 2025 | Dec 14, 2026 | May 7, 2026 | 2 | United States |
| NCT07525791 | A Research Study Looking Into How NNC0662-0419 Works With Birth Control Pills and Emptying of the Stomach in Women Not Able to Become Pregnant With Excess Body Weight | PHASE1 | RECRUITING | 45 | — | — | Apr 7, 2026 | May 4, 2027 | Apr 24, 2026 | 1 | United States |
| NCT07101783 | A Research Study on How a Dose of NNC0662-0419 Works in Japanese, Chinese and Non-Asian Participants Living With Overweight or Obesity | PHASE1 | COMPLETED | 100 | — | — | Aug 1, 2025 | Oct 31, 2025 | Dec 23, 2025 | 1 | United States |
| NCT06737536 | A First-in-human Research Study on How NNC0662-0419 Works in People Living With Overweight or Obesity | PHASE1 | COMPLETED | 100 | — | — | Dec 18, 2024 | Jul 26, 2025 | Sep 19, 2025 | 1 | United States |
Measured as number of events.
Measured as percentage (%).
Measured as count of participants.
Measured as picograms per milliliter (h\*pg/mL)
Measured as h\*pg/mL
Measured in hours\*nanomoles per liter (h\*nmol/L).
Number of events
Number of events
| Arm | Type | Description |
|---|---|---|
| NNC0662-0419 | EXPERIMENTAL | Participants will be randomized to receive NNC0662-0419 subcutaneously (s.c.). The study will be conducted in 3 parts. Part A: Multiple ascending dose (MAD), Part B: Dose range finding (DFR) and Part C (2-week escalation). |
| Placebo | PLACEBO_COMPARATOR | Participant will be randomized to receive placebo in: The study will be conducted in 3 parts. Part A: Multiple ascending dose (MAD), Part B: Dose range finding (DFR) and Part C (2-week escalation). |
| NNC0662-0419 with oral contraceptive (Altavera) and acetaminophen | EXPERIMENTAL | Participants will receive once-weekly subcutaneous NNC0662-0419, with multiple doses administered over the treatment period. An oral contraceptive will be administered as a number of tablets per treatment period, with dosing conducted under supervised conditions. In addition, a single dose of acetaminophen will be administered as part of a standardized meal during treatment period. |
| NNC0662-0419 (Dose 1) | EXPERIMENTAL | Participants will receive a single dose (SD) of NNC0662-0419 subcutaneously. |
| NNC0662-0419 (Dose 2) | EXPERIMENTAL | Participants will receive a SD of NNC0662-0419 subcutaneously. |
| NNC0662-0419 (Dose 3) | EXPERIMENTAL | Participants will receive a SD of NNC0662-0419 subcutaneously. |
| Part A: Single ascending dose (SAD) | EXPERIMENTAL | Participants will receive a single dose of any of the five different dose levels of NNC0662-0419 or matching placebo in a sequential manner with the dose increasing between cohorts. |
| Part B: Multiple ascending dose (MAD) | EXPERIMENTAL | Participants will receive NNC0662-0419 once-weekly for 4 weeks at any of the four different dose levels or matching placebo in a sequential manner with the dose increasing between cohorts. |
| Name | Type | Description |
|---|---|---|
| NNC0662-0419 | DRUG | NNC0662-0419 will be administered subcutaneously. |
| Placebo | DRUG | Placebo matched to NNC0662-0419 will be administered subcutaneously. |
| Oral contraceptive | DRUG | An oral contraceptive Altavera \[levonorgestrel (LN) 0.15 milligram (mg) and ethinyl estradiol (EE) 0.03 mg\] will be administered orally. |
| Acetaminophen | DRUG | A single dose of acetaminophen will be administered orally. |
| Placebo (NNC0662-0419) | OTHER | Participants will receive placebo matched to NNC0662-0419 s.c. once weekly. |
Inclusion criteria * Male or female (sex at birth). * Age at the time of signing the informed consent: * For Part A:18-55 years (both inclusive) * For Part B and Part C: 18-65 years (both inclusive) * Body Mass Index (BMI) at screening (overweight should be due to excess adipose tissue, as jud...